brincidofovir + tecovirimat

Brincidofovir + tecovirimat is a combination of two oral antiviral small molecules used primarily for the treatment of severe or life-threatening orthopoxvirus infections, including mpox (monkeypox) and smallpox. Brincidofovir is a lipid-conjugated prodrug of cidofovir that, once inside host cells, is cleaved to release cidofovir and subsequently phosphorylated to its active form, cidofovir diphosphate. This metabolite selectively inhibits viral DNA polymerase-mediated DNA synthesis in orthopoxviruses, thereby reducing viral replication. Tecovirimat targets the orthopoxvirus VP37 envelope wrapping protein, inhibiting virus maturation and egress from infected cells. The combination has demonstrated synergistic effects in improving viral suppression and reducing resistance risk compared to monotherapy. It is especially considered for immunocompromised patients or those with disease progression despite monotherapy[3][4][6].

Other names

brincidofovir + tecovirimat